Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.

Inclusion Criteria:

• Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.
• Must have acceptable organ and marrow function per protocol parameters.
• No clinically significant ventricular arrythmias or ischemia.

Exclusion Criteria:

• Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..
• No previous radiation to >25% of total bone marrow.
• No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation.
• No primary brain tumors or active brain metastases.
• No use of any investigational agents within 4 weeks.
• No treatment with chronic immunosuppressants.
• No uncontrolled, intercurrent illness.